SYNGENE Q2 FY25 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹891 Cr
verified against source
Revenue YoY
-2%
reported change
EBITDA
₹245 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Syngene reported Q2 FY25 revenue of INR 891 crore, down 2% YoY (-3% in constant currency), with EBITDA of INR 245 crore and PAT of INR 106 crore, declining 9% YoY. The quarter showed encouraging sequential improvement with 13% revenue growth vs Q1, driven by early-stage discovery services recovery. Management highlighted a 35% YoY increase in client audits to 60 in H1, with ~1/3 of RFPs opting for China-independent supply chains—a trend accelerated by the Biosecure Act's 2032 deadline. The Stelis biologics facility remains on track for H2 commissioning. Guidance is maintained for full-year revenue growth of high single-digit to low double-digit, though growth is expected at the lower half of this range, with margins recovering to approximately FY24 levels. The CFO transition from Sibaji Biswas to Deepak Jain was announced.
Colored figures show movement against the previous available record.
Guidance to track
- Revenue growth guidance maintained, but management expects outcomes at the lower half of the guided range based on current visibility, with momentum building in H2.
- H1 margin was 25% vs 27% last year; margin recovery expected in H2 driven by sequential revenue growth and operating leverage.
- Q2 CapEx was $12 million; bulk of spending directed toward biologics facility upgrade (Unit 3) and research services expansion in Hyderabad.
- The Stelis acquisition facility is on track for commissioning in the second half, converting from vaccine production capability to antibody manufacturing.
Risks flagged
- The newly acquired biologics facility requires time to ramp up client engagements and reach meaningful utilization; revenue contribution may be limited in initial quarters post-commissioning.
- Discovery services recovery is driven by pilot projects with multiple partners being evaluated; conversion to long-term contracts typically takes 12-18 months and success is not guaranteed.
- Entry of generics companies and private equity-backed players into Indian CDMO space could intensify pricing pressure and talent competition, though management expressed confidence in Syngene's established capabilities.
- Sibaji Biswas noted to be departing after five years; incoming CFO Deepak Jain has only been with the company one month. Financial stewardship continuity during this transition period presents execution risk.
Key quotes
- I think it's a bit too soon to declare victory, so we'll have to wait and watch that for a little bit longer.
- We have been indicating over the last couple of quarters that we are building up a healthy pipeline for all parts of our business. We do expect healthy growth of discovery services, both on sequential basis and year-on-year basis.
- It's not an overnight sensation, but it's a really positive tailwind on the industry for those of us that have got capacity in this part of the world and outside of China.
Research modules